Research
Mixed
Combining SGLT2 inhibitors with GLP-1 receptor agonists results in greater weight loss and HbA1c reduction than using either drug alone.
If one medication isn't enough to control your blood sugar and weight, ask about combining an SGLT2 inhibitor with a GLP-1 agonist. Studies show this combo leads to more weight loss (around 3.4 kg in trials) and better blood sugar control than using either drug alone.
GoodSupportsHIGH confidence
the results of the DURATION 8 study showed that a combination of dapagliflozin (an SGLT2i) once daily and exenatide (a GLP-1 RA) once weekly on a background of metformin treatment resulted in a 2% reduction in HbA1c and a weight loss of 3.4 kg after 28 weeks of administration; importantly, these beneficial changes were greater following combined therapy than when these drugs were used in monotherapy [24].
Why this rating
Based on a specific Phase 3 RCT (DURATION 8) cited.
Source
Medication use for the treatment of diabetes in obese individuals
John Wilding · Diabetologia · 2017
narrative_reviewCited 43×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →